<div id="readability-page-1"><p>LifeSci Capital analyst Charles Zhu maintained a Buy rating on Kura Oncology today and set a price target of $28.00.</p><h3>Claim 30% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Charles Zhu has given his Buy rating due to a combination of factors tied to Kura’s emerging clinical data and strategic positioning in renal cell carcinoma. He views the updated results from the FIT-001 study, where darlifarnib is combined with cabozantinib in post-cabo clear cell RCC, as particularly compelling because the response rates materially exceed what would be expected from cabozantinib retreatment alone.</p> <p>Zhu also highlights that several responses occurred in patients who had previously derived only stable disease or who had recently progressed on cabozantinib, suggesting meaningful resensitization to VEGF TKI therapy. In his view, the manageable safety profile at full-dose cabozantinib, early signals of durability, and evidence of investigator enthusiasm in a high-unmet-need, post-IO setting together support a favorable risk‑reward and justify a continued Buy recommendation on KURA.</p> </div>

KURA

LABU

IBBQ

ARKG

SBIO

<p>LifeSci Capital analyst Charles Zhu has maintained a Buy rating on Kura Oncology, setting a price target of $28.00. His recommendation is based on promising clinical data from the FIT-001 study, where the combination of darlifarnib and cabozantinib showed response rates exceeding expectations. Zhu notes the manageable safety profile and early signs of treatment durability, supporting a favorable risk-reward scenario in the post-IO renal cell carcinoma setting.</p>

- Analyst Charles Zhu from LifeSci Capital maintains a "Buy" rating on Kura Oncology with a target price of $28.00, based on new clinical data and its strategic positioning in renal cell carcinoma.  
- Zhu highlights promising results from the FIT-001 study, where the combination of darlifarnib and cabozantinib achieved response rates exceeding expectations for previously treated patients.  
- He concludes that the manageable safety profile of cabozantinib and positive early tolerability signals support a favorable risk-reward outlook, justifying his continued recommendation to buy KURA.

Tip Ranks

Kura Oncology

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating